These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24613488)

  • 1. Mapping of the binding landscape for a picomolar protein-protein complex through computation and experiment.
    Aizner Y; Sharabi O; Shirian J; Dakwar GR; Risman M; Avraham O; Shifman J
    Structure; 2014 Apr; 22(4):636-45. PubMed ID: 24613488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, expression and characterization of mutants of fasciculin optimized for interaction with its target, acetylcholinesterase.
    Sharabi O; Peleg Y; Mashiach E; Vardy E; Ashani Y; Silman I; Sussman JL; Shifman JM
    Protein Eng Des Sel; 2009 Oct; 22(10):641-8. PubMed ID: 19643977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target.
    Harel M; Kleywegt GJ; Ravelli RB; Silman I; Sussman JL
    Structure; 1995 Dec; 3(12):1355-66. PubMed ID: 8747462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico analysis of binding of neurotoxic venom ligands with acetylcholinesterase for therapeutic use in treatment of Alzheimer's disease.
    Waqar M; Batool S
    J Theor Biol; 2015 May; 372():107-17. PubMed ID: 25747777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II.
    Kryger G; Harel M; Giles K; Toker L; Velan B; Lazar A; Kronman C; Barak D; Ariel N; Shafferman A; Silman I; Sussman JL
    Acta Crystallogr D Biol Crystallogr; 2000 Nov; 56(Pt 11):1385-94. PubMed ID: 11053835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theoretical analysis of the structure of the peptide fasciculin and its docking to acetylcholinesterase.
    van den Born HK; Radić Z; Marchot P; Taylor P; Tsigelny I
    Protein Sci; 1995 Apr; 4(4):703-15. PubMed ID: 7613468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterization of a chimeric peptide derived from fasciculin that inhibits acetylcholinesterase.
    Falkenstein RJ; Gornalusse GG; Peña C
    J Pept Sci; 2004 Jun; 10(6):342-9. PubMed ID: 15214439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational transitions in protein-protein association: binding of fasciculin-2 to acetylcholinesterase.
    Bui JM; Radic Z; Taylor P; McCammon JA
    Biophys J; 2006 May; 90(9):3280-7. PubMed ID: 16473897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic peptides mimicking the binding site of human acetylcholinesterase for its inhibitor fasciculin 2.
    Kafurke U; Erijman A; Aizner Y; Shifman JM; Eichler J
    J Pept Sci; 2015 Sep; 21(9):723-30. PubMed ID: 26200472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The fasciculin-acetylcholinesterase interaction].
    Marchot P
    J Soc Biol; 1999; 193(6):505-8. PubMed ID: 10783708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex.
    Bourne Y; Taylor P; Marchot P
    Cell; 1995 Nov; 83(3):503-12. PubMed ID: 8521480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen-bonding interactions in the binding of loop 1 of fasciculin 2 to Torpedo californica acetylcholinesterase: a density functional theory study.
    Wang J; Gu J; Leszczynski J
    J Phys Chem B; 2005 Jul; 109(28):13761-9. PubMed ID: 16852724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble monomeric acetylcholinesterase from mouse: expression, purification, and crystallization in complex with fasciculin.
    Marchot P; Ravelli RB; Raves ML; Bourne Y; Vellom DC; Kanter J; Camp S; Sussman JL; Taylor P
    Protein Sci; 1996 Apr; 5(4):672-9. PubMed ID: 8845756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and activity of mutants of fasciculin, a peptidic acetylcholinesterase inhibitor from mamba venom.
    Marchot P; Prowse CN; Kanter J; Camp S; Ackermann EJ; Radić Z; Bougis PE; Taylor P
    J Biol Chem; 1997 Feb; 272(6):3502-10. PubMed ID: 9013597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic peptides derived from the central loop of fasciculin: structural analysis and evaluation as inhibitors of acetylcholinesterase.
    Falkenstein RJ; Peña C
    Biochim Biophys Acta; 1997 Jun; 1340(1):143-51. PubMed ID: 9217024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site of fasciculin interaction with acetylcholinesterase.
    Radić Z; Duran R; Vellom DC; Li Y; Cervenansky C; Taylor P
    J Biol Chem; 1994 Apr; 269(15):11233-9. PubMed ID: 8157652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases.
    Saxena A; Qian N; Kovach IM; Kozikowski AP; Pang YP; Vellom DC; Radić Z; Quinn D; Taylor P; Doctor BP
    Protein Sci; 1994 Oct; 3(10):1770-8. PubMed ID: 7849595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting affinity- and specificity-enhancing mutations at protein-protein interfaces.
    Sharabi O; Shirian J; Shifman JM
    Biochem Soc Trans; 2013 Oct; 41(5):1166-9. PubMed ID: 24059503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of the neurotoxin fasciculin 2 to the acetylcholinesterase peripheral site drastically reduces the association and dissociation rate constants for N-methylacridinium binding to the active site.
    Rosenberry TL; Rabl CR; Neumann E
    Biochemistry; 1996 Jan; 35(3):685-90. PubMed ID: 8547248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholinesterase: enhanced fluctuations and alternative routes to the active site in the complex with fasciculin-2.
    Bui JM; Tai K; McCammon JA
    J Am Chem Soc; 2004 Jun; 126(23):7198-205. PubMed ID: 15186156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.